A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/506 (2006.01) A61K 31/519 (2006.01) A61K 45/00 (2006.01) A61P 35/02 (2006.01) A61P 43/00 (2006.01)
Patent
CA 2450777
The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino- methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family,the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}- 4-(3-pyridyl)-2-pyrimidine-amine.
L'invention concerne une combinaison qui comporte (a) au moins un composé diminuant l'activité de c-Src et (b) N-{5-[4-(4-méthyl-pipérazino-méthyl)-benzoylamido]-2-méthylphényl}-4-(3-pyridyl)-2-pyrimidine-amine ou le sel monométhanesulfonate de celui-ci, des compositions pharmaceutiques comprenant lesdites combinaisons; et un procédé de traitement d'un animal à sang chaud souffrant de leucémies, en particulier la leucémie myélogène chronique, qui consiste à administrer à l'animal au moins un composé inhibant l'activité d'un élément de la famille des kinases Src, la famille des kinases Btk, la famille des kinases Tec ou un inhibiteur des kinases Raf, inhibant en particulier l'activité de la protéine tyrosine kinase c-Src ou, simultanément, l'activité de la protéine tyrosine kinase c-Src et l'activité de la tyrosine kinase Bcr-Abl, seul ou en combinaison avec un inhibiteur Bcr-Abl, en particulier N-{5-[4-(4-méthyl-pipérazino-méthyl)-benzoylamido]-2-méthylphényl}-4-(3-pyridyl)-2-pyrimidine-amine.
Donato Nicholas J.
Fabbro Doriano
Hallek Michael
Manley Paul William
Mestan Juergen
Fetherstonhaugh & Co.
Gsf - National Research Institute For Environment And Health
Novartis Ag
The University Of Texas System
LandOfFree
Use of c-src inhibitors alone or in combination with sti571... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of c-src inhibitors alone or in combination with sti571..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of c-src inhibitors alone or in combination with sti571... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1676022